Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryptococcus neoformans | 25 | 2025 | 34 | 8.010 |
Why?
|
| Cryptococcosis | 24 | 2025 | 32 | 6.670 |
Why?
|
| Antifungal Agents | 7 | 2025 | 67 | 2.160 |
Why?
|
| Dendritic Cells | 8 | 2021 | 142 | 2.080 |
Why?
|
| Lung Diseases, Fungal | 11 | 2018 | 14 | 2.070 |
Why?
|
| Host-Pathogen Interactions | 6 | 2021 | 91 | 1.770 |
Why?
|
| Lysosomes | 3 | 2021 | 56 | 1.400 |
Why?
|
| Anti-Infective Agents | 3 | 2024 | 78 | 1.370 |
Why?
|
| Mice, Inbred BALB C | 18 | 2021 | 276 | 1.050 |
Why?
|
| Interleukin-17 | 5 | 2014 | 52 | 0.970 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2025 | 148 | 0.950 |
Why?
|
| Mice | 30 | 2024 | 4654 | 0.950 |
Why?
|
| Phagocytes | 2 | 2022 | 15 | 0.950 |
Why?
|
| Animals | 34 | 2025 | 10423 | 0.890 |
Why?
|
| T-Lymphocytes | 4 | 2016 | 282 | 0.850 |
Why?
|
| Macrophages, Alveolar | 7 | 2021 | 36 | 0.820 |
Why?
|
| Cytokines | 10 | 2024 | 447 | 0.790 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 524 | 0.780 |
Why?
|
| Lung | 10 | 2019 | 379 | 0.660 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 403 | 0.650 |
Why?
|
| Candida albicans | 6 | 2024 | 48 | 0.640 |
Why?
|
| Proteins | 1 | 2021 | 252 | 0.620 |
Why?
|
| Antibodies, Fungal | 6 | 2010 | 9 | 0.590 |
Why?
|
| Macrophage Activation | 6 | 2018 | 32 | 0.560 |
Why?
|
| Immunity, Cellular | 3 | 2015 | 23 | 0.560 |
Why?
|
| Candidiasis, Vulvovaginal | 3 | 2012 | 3 | 0.550 |
Why?
|
| Neutrophils | 4 | 2012 | 181 | 0.530 |
Why?
|
| Microbial Viability | 3 | 2012 | 29 | 0.500 |
Why?
|
| Antimony | 3 | 2024 | 4 | 0.480 |
Why?
|
| STAT1 Transcription Factor | 4 | 2018 | 38 | 0.480 |
Why?
|
| Candida | 3 | 2010 | 22 | 0.460 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 74 | 0.450 |
Why?
|
| Peptides | 2 | 2014 | 288 | 0.440 |
Why?
|
| Female | 21 | 2023 | 15156 | 0.440 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 1461 | 0.420 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 9 | 0.410 |
Why?
|
| Interleukin-10 | 2 | 2024 | 72 | 0.410 |
Why?
|
| Antigens, Fungal | 2 | 2009 | 6 | 0.360 |
Why?
|
| Cryptococcus | 2 | 2019 | 2 | 0.350 |
Why?
|
| Phagocytosis | 4 | 2021 | 80 | 0.320 |
Why?
|
| Interferon-gamma | 4 | 2019 | 107 | 0.320 |
Why?
|
| Candidiasis | 2 | 2005 | 25 | 0.310 |
Why?
|
| Humans | 17 | 2024 | 28097 | 0.310 |
Why?
|
| Mice, Knockout | 6 | 2024 | 848 | 0.300 |
Why?
|
| Endosomes | 1 | 2008 | 45 | 0.290 |
Why?
|
| Fungal Vaccines | 3 | 2016 | 8 | 0.270 |
Why?
|
| Oximes | 2 | 2024 | 8 | 0.260 |
Why?
|
| Lectins, C-Type | 2 | 2017 | 43 | 0.260 |
Why?
|
| Vaginitis | 1 | 2005 | 3 | 0.250 |
Why?
|
| Moths | 1 | 2025 | 13 | 0.240 |
Why?
|
| Staphylococcus aureus | 2 | 2024 | 118 | 0.240 |
Why?
|
| Receptors, Immunologic | 2 | 2017 | 72 | 0.240 |
Why?
|
| Escherichia coli | 2 | 2024 | 337 | 0.230 |
Why?
|
| Klebsiella pneumoniae | 1 | 2024 | 29 | 0.220 |
Why?
|
| Polyethyleneimine | 1 | 2024 | 18 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2005 | 161 | 0.220 |
Why?
|
| Inflammation | 5 | 2024 | 636 | 0.210 |
Why?
|
| Bacteria | 2 | 2024 | 281 | 0.210 |
Why?
|
| Cardiomyopathies | 1 | 2024 | 33 | 0.210 |
Why?
|
| Gram-Negative Bacteria | 1 | 2024 | 62 | 0.210 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 157 | 0.210 |
Why?
|
| Monocytes | 1 | 2024 | 135 | 0.210 |
Why?
|
| Triticum | 1 | 2023 | 20 | 0.200 |
Why?
|
| Th1 Cells | 3 | 2014 | 36 | 0.200 |
Why?
|
| Signal Transduction | 5 | 2018 | 1435 | 0.200 |
Why?
|
| Candidiasis, Oral | 1 | 2002 | 2 | 0.200 |
Why?
|
| Pharyngeal Diseases | 1 | 2002 | 5 | 0.200 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 11 | 0.200 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2002 | 10 | 0.190 |
Why?
|
| Antigen Presentation | 1 | 2022 | 78 | 0.190 |
Why?
|
| Immunity, Innate | 2 | 2021 | 226 | 0.190 |
Why?
|
| Cells, Cultured | 5 | 2021 | 985 | 0.190 |
Why?
|
| Fungal Proteins | 3 | 2009 | 82 | 0.190 |
Why?
|
| Lung Diseases | 2 | 2014 | 43 | 0.190 |
Why?
|
| Saliva | 1 | 2002 | 96 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 1576 | 0.190 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.190 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 49 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 247 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 59 | 0.180 |
Why?
|
| Lyme Disease | 1 | 2021 | 26 | 0.180 |
Why?
|
| Borrelia burgdorferi | 1 | 2021 | 28 | 0.180 |
Why?
|
| Flow Cytometry | 3 | 2016 | 289 | 0.160 |
Why?
|
| Hyphae | 3 | 2015 | 8 | 0.160 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 80 | 0.160 |
Why?
|
| Prognosis | 1 | 2021 | 803 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2019 | 58 | 0.150 |
Why?
|
| Vagina | 2 | 2012 | 42 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2015 | 288 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 285 | 0.140 |
Why?
|
| Male | 4 | 2021 | 13491 | 0.140 |
Why?
|
| Macrophages | 1 | 2020 | 295 | 0.140 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 485 | 0.130 |
Why?
|
| Intracellular Space | 2 | 2016 | 12 | 0.130 |
Why?
|
| Virulence | 3 | 2021 | 151 | 0.130 |
Why?
|
| Coccidioides | 1 | 2016 | 14 | 0.130 |
Why?
|
| Interleukins | 2 | 2014 | 112 | 0.130 |
Why?
|
| Coccidioidomycosis | 1 | 2016 | 13 | 0.120 |
Why?
|
| Cryptococcus gattii | 1 | 2014 | 1 | 0.120 |
Why?
|
| Mice, Inbred CBA | 2 | 2005 | 11 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2014 | 12 | 0.110 |
Why?
|
| Glycation End Products, Advanced | 1 | 2014 | 17 | 0.110 |
Why?
|
| Cell Wall | 2 | 2012 | 67 | 0.110 |
Why?
|
| Cytoprotection | 2 | 2011 | 24 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 72 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2012 | 4 | 0.100 |
Why?
|
| Osmosis | 1 | 2012 | 7 | 0.100 |
Why?
|
| Cell Extracts | 1 | 2012 | 14 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 40 | 0.100 |
Why?
|
| Chemokines | 1 | 2012 | 74 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2011 | 35 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 8 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 15 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2011 | 33 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2002 | 270 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 1054 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 769 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 34 | 0.080 |
Why?
|
| Vaccination | 3 | 2019 | 186 | 0.080 |
Why?
|
| Blood Proteins | 1 | 2010 | 68 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2024 | 659 | 0.080 |
Why?
|
| Leukocytes | 1 | 2009 | 71 | 0.080 |
Why?
|
| Mycology | 1 | 2009 | 2 | 0.080 |
Why?
|
| Carbohydrate Sequence | 1 | 2009 | 14 | 0.080 |
Why?
|
| Mannans | 1 | 2009 | 4 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 17 | 0.080 |
Why?
|
| Opsonin Proteins | 1 | 2008 | 5 | 0.080 |
Why?
|
| Microscopy, Video | 1 | 2008 | 18 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2008 | 73 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 24 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2009 | 62 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 82 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 113 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2010 | 252 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 145 | 0.070 |
Why?
|
| Vaccines, Attenuated | 2 | 2016 | 7 | 0.060 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2024 | 2 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2024 | 119 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2024 | 208 | 0.060 |
Why?
|
| Time Factors | 1 | 2008 | 1592 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2024 | 33 | 0.060 |
Why?
|
| Crystallography, X-Ray | 1 | 2024 | 222 | 0.060 |
Why?
|
| Nitric Oxide | 2 | 2015 | 152 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2024 | 243 | 0.050 |
Why?
|
| Estrogens | 1 | 2024 | 56 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2024 | 71 | 0.050 |
Why?
|
| Diet, Atherogenic | 1 | 2023 | 3 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 15 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 28 | 0.050 |
Why?
|
| Body Fluids | 1 | 2002 | 18 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2002 | 19 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2002 | 23 | 0.050 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2002 | 2 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 13 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2024 | 259 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2002 | 114 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 137 | 0.050 |
Why?
|
| Phenotype | 2 | 2019 | 681 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2014 | 391 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2021 | 61 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2021 | 74 | 0.040 |
Why?
|
| Peptidoglycan | 1 | 2021 | 47 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 49 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 254 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 632 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 95 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 102 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 2016 | 9 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2016 | 11 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2015 | 4 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2015 | 3 | 0.030 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2015 | 25 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 40 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 209 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2014 | 15 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 12 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2014 | 40 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 124 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 131 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 507 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 114 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 578 | 0.030 |
Why?
|
| Interleukin-23 | 1 | 2012 | 8 | 0.030 |
Why?
|
| Disease Resistance | 1 | 2012 | 18 | 0.020 |
Why?
|
| Calgranulin A | 1 | 2012 | 10 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2012 | 17 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 60 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 765 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 257 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 847 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 463 | 0.020 |
Why?
|
| Drug Resistance, Fungal | 1 | 2010 | 16 | 0.020 |
Why?
|
| Organisms, Genetically Modified | 1 | 2010 | 5 | 0.020 |
Why?
|
| Fluconazole | 1 | 2010 | 9 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 82 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 328 | 0.020 |
Why?
|
| Transgenes | 1 | 2010 | 63 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 692 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2005 | 26 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2005 | 37 | 0.020 |
Why?
|
| Neutropenia | 1 | 2005 | 41 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2005 | 46 | 0.010 |
Why?
|
| Virulence Factors | 1 | 2005 | 45 | 0.010 |
Why?
|
| Surface Properties | 1 | 2005 | 134 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 248 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 2379 | 0.010 |
Why?
|